Related Experiment Videos
Haemodynamic effects of nitroglycerin infusion in patients with postinfarction heart failure
Insights
Intravenous nitroglycerin (NTG) effectively reduces left ventricular filling pressure in patients with postinfarction heart failure. However, careful dosage control and monitoring are crucial due to potential effects on cardiac index and blood pressure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Postinfarction heart failure presents significant challenges in hemodynamic management.
- Intravenous nitroglycerin (NTG) is a vasodilator with potential applications in managing cardiac dysfunction.
Purpose of the Study:
- To evaluate the indications and limitations of intravenous nitroglycerin infusion in patients with postinfarction heart failure.
- To assess the hemodynamic effects of NTG on left ventricular filling pressure, cardiac index, mean arterial pressure, and peripheral resistance.
Main Methods:
- A 5-year clinical experience involving 42 patients with postinfarction heart failure was analyzed.
- Hemodynamic parameters including left ventricular filling pressure, cardiac index, mean arterial pressure, and peripheral resistance were monitored during NTG infusion.
Main Results:
- Intravenous NTG significantly reduced left ventricular filling pressure in all patients, irrespective of baseline levels.
- In patients with normal or mildly elevated filling pressures, NTG decreased cardiac index and mean arterial pressure, with an initial increase in peripheral resistance.
- Similar hemodynamic trends were observed in patients with markedly elevated filling pressures when mean arterial blood pressure decreased by over 20%.
Conclusions:
- Intravenous nitroglycerin infusion is primarily indicated for manifest heart failure.
- Effective NTG dosage ranged widely (15-150 micrograms/min), necessitating strict dose control and therapeutic effect monitoring.
- Careful administration and monitoring are essential to optimize NTG's use in postinfarction heart failure.
Abstract:
On the basis of their own 5-year experience, the authors discuss the indications for, and limitations of, intravenous infusion of nitroglycerin (NTG). In 42 patients with postinfarction heart failure, NTG produced a significant reduction of left ventricular filling pressure, regardless of its initial value. In patients with normal or only slightly elevated left ventricular filling pressure, NTG caused a decrease in cardiac index and mean arterial pressure as well as, in the earliest phase of infusion, an increase in peripheral resistance. Similar trends were observed also in patients with markedly elevated left ventricular filling pressure if mean arterial blood pressure fell by more than 20%. Taking into consideration that the range of the effective doses was very wide (15-150 micrograms/min), the authors believe that intravenous NTG infusion is indicated mainly in cases of manifest heart failure and should be administered under strict control of the dosage and with careful monitoring of the therapeutic effects.